(Q37887819)

24 August 2017

1 reference

title

Monoclonal antibodies and antibody fragments: state of the art and future perspectives in the treatment of non-haematological tumors (English)

1 reference

24 August 2017

1 reference

6

1 reference

24 August 2017

7

Viviana Bazan

1 reference

24 August 2017

Gaetana Di Fede

1

1 reference

24 August 2017

Giuseppe Bronte

2

1 reference

24 August 2017

Sergio Rizzo

3

1 reference

24 August 2017

Christian Rolfo Cervetto

4

1 reference

24 August 2017

Gianfranco Cocorullo

5

1 reference

24 August 2017

Antonio Russo

8

1 reference

24 August 2017

language of work or name

English

0 references

publication date

12 June 2011

1 reference

Expert Opinion on Biological Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

11

1 reference

24 August 2017

page(s)

1433-1445

1 reference

Antibodies and their fragments as anti-cancer agents

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

With the benefit of hindsight

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

21 January 2018

Engineered antibodies

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Tumor angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

The von Hippel-Lindau protein, HIF hydroxylation, and oxygen sensing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Vascular endothelial growth factor is essential for corpus luteum angiogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

The biology of VEGF and its receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Rapid vascular regrowth in tumors after reversal of VEGF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Gastrointestinal perforation due to bevacizumab in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Tumor metastasis: mechanistic insights and clinical challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Trastuzumab Improves the Efficacy of Chemotherapy in Breast Cancer Treatment beyond Progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Cetuximab for the treatment of colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Platinum-based chemotherapy plus cetuximab in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Antibodies to watch in 2010

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Anti-idiotype immunization of cancer patients: modulation of the immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Adjuvant therapy with the monoclonal antibody Edrecolomab plus fluorouracil-based therapy does not improve overall survival of patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Pertuzumab for the treatment of ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Characterisation of the new EpCAM-specific antibody HO-3: implications for trifunctional antibody immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Drug delivery and transport to solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Production of soluble ScFvs with C-terminal-free thiol for site-specific conjugation or stable dimeric ScFvs on demand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Crystal structure of a diabody, a bivalent antibody fragment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Antibody-dependent cellular cytotoxicity of cetuximab against tumor cells with wild-type or mutant epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Adjuvant Therapy with Edrecolomab versus Observation in Stage II Colon Cancer: A Multicenter Randomized Phase III Study*

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

Human IgG2 Antibodies against Epidermal Growth Factor Receptor Effectively Trigger Antibody-Dependent Cellular Cytotoxicity but, in Contrast to IgG1, Only by Cells of Myeloid Lineage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2011.594436

10.1517/14712598.2011.594436

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference